Covid 19 Research using Clinical Trials (Home Page)
MSCsWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug928 | bacTRL-Spike Wiki | 0.71 |
| drug727 | Saline containing 1% Human serum albumin（solution of MSC） Wiki | 0.71 |
| drug616 | Placebo Wiki | 0.07 |
There are 2 clinical trials
Clinical Trials
1 Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19
The SARS-CoV-2 infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. There is no confirmed antivirus therapy for people infected SARS-CoV-2, most of them should receive supportive care to help relieve symptoms. For severe cases, treatment should include care to support vital organ functions. This clinical trial is to inspect the safety and efficiency of Mesenchymal Stem Cells (MSCs) therapy for pneumonia patients infected with SARS-CoV-2.
NCT04252118 COVID-19 Biological: MSCs MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: Evaluation of Pneumonia Improvement
Measure: Size of lesion area by chest radiograph or CT Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21，Day 28
Description: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Measure: Side effects in the MSCs treatment group Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180
Secondary Outcomes
Description: Evaluation of Pneumonia Improvement
Measure: Improvement of Clinical symptoms including duration of fever and respiratory Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28
Description: Marker for COVID-19
Measure: Time of nucleic acid turning negative Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180
Description: Marker for efficacy of treatment
Measure: Rate of mortality within 28-days Time: Day 28
Description: Marker of Immunological function
Measure: CD4+ and CD8+ T celll count Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180
Description: Markers of organ function
Measure: Alanine aminotransferase Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180
Description: Markers of Infection
Measure: C-reactive protein Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180
Description: Markers of organ function
Measure: Creatine kinase Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180
2 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination With Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence
Primary Outcomes
Description: Evaluation of Pneumonia Improvement
Measure: Size of lesion area by chest radiograph or CT Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21，Day 28Description: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Measure: Side effects in the MSCs treatment group Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180Secondary Outcomes
Description: Evaluation of Pneumonia Improvement
Measure: Improvement of Clinical symptoms including duration of fever and respiratory Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28Description: Marker for COVID-19
Measure: Time of nucleic acid turning negative Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180Description: Marker for efficacy of treatment
Measure: Rate of mortality within 28-days Time: Day 28Description: Marker of Immunological function
Measure: CD4+ and CD8+ T celll count Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180Description: Markers of organ function
Measure: Alanine aminotransferase Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180Description: Markers of Infection
Measure: C-reactive protein Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180Description: Markers of organ function
Measure: Creatine kinase Time: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 21, Day 28, Day 90 and Day 180COVID-19 caused clusters of severe respiratory illness and was associated with 2% mortality. No specific anti-viral treatment exists. The mainstay of clinical management is largely symptomatic treatment, with organ support in intensive care for seriously ill patients. Cellular therapy, using mesenchymal stem cells has been shown to reduce nonproductive inflammation and affect tissue regeneration and is being evaluated in patients with ARDS. This clinical trial is to inspect the safety and efficiency of mesenchymal stem cells (MSCs) therapy for severe COVID-19.
NCT04288102 Corona Virus Disease 2019(COVID-19) Biological: MSCs Biological: Saline containing 1% Human serum albumin（solution of MSC） MeSH:Coronavirus Infections Virus Diseases
Primary Outcomes
Description: Evaluation of Pneumonia Improvement
Measure: Size of lesion area and severity of pulmonary fibrosis by chest CT Time: At Baseline , Day 6, Day 10, Day 14, Day 28 and Day 90Secondary Outcomes
Description: Evaluation of Pneumonia Improvement No limitation of activities, discharged from hospital =Score 1; Hospitalized, no oxygen therapy=Score 2; Oxygen by mask or nasal prongs-Score 3; Non-invasive ventilation or high-flow oxygen=Score 4; Mechanical ventilation or ECMO=Score 5; Death=Score 6.
Measure: mMRC (Modified Medical Research Council) dyspnea scale Time: Baseline , Day 7, Day 14, Day 28, Day 90Description: Evaluation of Pneumonia Improvement
Measure: Oxygenation index( PaO2/FiO2) Time: Baseline , Day 7, Day 14, Day 28, Day 90Description: Evaluation of Pneumonia Improvement
Measure: Duration of oxygen therapy(days) Time: Day 28, Day 90Description: Evaluation of Pneumonia Improvement
Measure: Duration of hospitalization(days) Time: Day 28, Day 90Description: Evaluation of Pneumonia Improvement
Measure: Blood oxygen saturation Time: Baseline , Day 7, Day 14, Day 28, Day 90Description: Marker of Immunological function
Measure: CD4+ T cell count and cytokine level Time: Baseline , Day 6, Day 10, Day 14, Day 21, Day 28, Day 90Description: Proportion of participants with treatment-related adverse events as assessed by CTCAE v4.0
Measure: Side effects in the MSCs treatment group Time: Baseline , Day 3, Day 6，Day 10, Day 14, Day 21, Day 28, Day 90Description: Evaluation of Pneumonia Improvement
Measure: 6-minute walk test Time: Baseline, Day 10, Day 14, Day 21, Day 28, Day 90Description: Evaluation of Pneumonia Improvement
Measure: Maximum vital capacity (VCmax) Time: Baseline, Day 10, Day 14, Day 21, Day 28, Day 90Description: Evaluation of Pneumonia Improvement
Measure: Diffusing Capacity (DLCO) Time: Baseline, Day 10, Day 14, Day 21, Day 28, Day 90